secwatch.observer — SEC 8-K summary
======================================

Issuer:     CARLSMED, INC. (CARL)
CIK:        0001794546
Form:       8-K
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0000950170-25-111947
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carlsmed Q2 revenue $12.1M (+99% YoY); raises FY guidance to $45.5M-$47.5M
--------------------------------------------------------------------------

- Q2 revenue $12.1M, up 99% YoY; gross margin 73.4%; net loss $6.8M.
- Cash $33.5M at June 30; $93.5M net from July 2025 IPO to fund growth.
- First personalized cervical spine surgery using aprevo completed; CMS NTAP reimbursement begins Oct 1, 2025.
- FY 2025 revenue guidance raised to $45.5M-$47.5M, representing 67-75% growth YoY.
- Adjusted EBITDA loss unchanged at $6.2M; operating expenses rose to $15.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1794546/000095017025111947/0000950170-25-111947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1794546/000095017025111947/carl-20250828.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-111947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer